| scholarly article | Q13442814 |
| P50 | author | Yoshihito Yokoyama | Q87618863 |
| Hideki Mizunuma | Q114250977 | ||
| P2093 | author name string | Bing Xin | |
| Masayuki Futagami | |||
| Tatsuhiko Shigeto | |||
| P2860 | cites work | Cyclooxygenase regulates angiogenesis induced by colon cancer cells | Q24336248 |
| cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase | Q24561546 | ||
| Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation | Q24642901 | ||
| Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer | Q24643602 | ||
| Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000 | Q24798597 | ||
| Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours | Q28209267 | ||
| Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2 | Q28299729 | ||
| Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2 | Q28585904 | ||
| Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors | Q34008146 | ||
| Aspirin use and reduced risk of fatal colon cancer | Q34567474 | ||
| PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer | Q34768343 | ||
| Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression | Q35735316 | ||
| Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma | Q35788745 | ||
| Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. | Q37366851 | ||
| Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. | Q38302731 | ||
| Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence | Q38438329 | ||
| Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists | Q38785265 | ||
| Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand | Q39708256 | ||
| Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer | Q40146298 | ||
| Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549. | Q40305196 | ||
| Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma | Q40409082 | ||
| Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta | Q40417113 | ||
| Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice | Q40590086 | ||
| Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer | Q40673230 | ||
| Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors | Q40678938 | ||
| Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth | Q40699776 | ||
| Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells | Q40938679 | ||
| Meloxicam inhibits the growth of colorectal cancer cells | Q40981381 | ||
| Demonstration That Mutation of the Type II Transforming Growth Factor β Receptor Inactivates Its Tumor Suppressor Activity in Replication Error-positive Colon Carcinoma Cells | Q41294837 | ||
| Moderate levels of ethanol induce expression of vascular endothelial growth factor and stimulate angiogenesis | Q43638809 | ||
| Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells | Q43726282 | ||
| The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells | Q43981126 | ||
| Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells | Q43992108 | ||
| Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis | Q44231772 | ||
| IL-1beta-dependent activation of NF-kappaB mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. | Q44512882 | ||
| Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells | Q44812587 | ||
| Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy | Q45125053 | ||
| Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes | Q46747952 | ||
| Cyclooxygenase-2 expression during carcinogenesis in the human stomach. | Q53393003 | ||
| Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. | Q53961800 | ||
| Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis | Q73642418 | ||
| Differentiation and reversal of malignant changes in colon cancer through PPARgamma | Q77291051 | ||
| Cyclooxygenase-2 inhibitors in tumorigenesis (part I) | Q77470864 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 791-800 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers | |
| P478 | volume | 110 |
| Q55463690 | Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells. |
| Q33583598 | Antivascular therapy for epithelial ovarian cancer |
| Q38826752 | Blocking autophagy enhances meloxicam lethality to hepatocellular carcinoma by promotion of endoplasmic reticulum stress |
| Q39522931 | Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers |
| Q39647685 | Combined Inhibitory Effects of Celecoxib and Fluvastatin on the Growth of Human Hepatocellular Carcinoma Xenografts in Nude Mice |
| Q34378095 | Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo |
| Q37646513 | Cyclooxygenase inhibitors: scope of their use and development in cancer chemotherapy |
| Q46262682 | Dietary aspirin decreases the stage of ovarian cancer in the hen. |
| Q52962540 | Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer. |
| Q37379342 | Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. |
| Q36401953 | Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation |
| Q33723620 | In vivo effects of rosiglitazone in a human neuroblastoma xenograft |
| Q34794017 | Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk |
| Q48600571 | Juvenile ovary to testis transition in zebrafish involves inhibition of ptges |
| Q37978771 | Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. |
| Q36798663 | PPARgamma and Proline Oxidase in Cancer |
| Q37157524 | Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer. |
| Q47752791 | Primary tumour growth in an orthotopic osteosarcoma mouse model is not influenced by analgesic treatment with buprenorphine and meloxicam |
| Q39193382 | Side effects of pain and analgesia in animal experimentation. |
| Q35954103 | Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer |
| Q39700563 | Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer |
| Q36983835 | Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer |
| Q28541515 | Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells |
| Q28551531 | The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic Cancers |
| Q58579152 | The Chemoprevention of Ovarian Cancer: the Need and the Options |
| Q37337997 | The Role of PPARs in the Endothelium: Implications for Cancer Therapy |
| Q33713908 | Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer |
| Q37306176 | Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts |
Search more.